# WU-KONG1 (NCT03974022)

> Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03974022
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dizal Pharmaceuticals
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Sunvozertinib
- Enrollment: 315
- Primary outcome: Part A Dose Escalation: Dose Limiting Toxicities (DLTs).
- Primary outcome: Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8
- YouTube: 3
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=wu-kong1-nct03974022

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03974022", "email": "<work email>"}; the inbox owner confirms by the emailed link.